SG11201503878XA - Monoclonal antibodies targeting neutralizing epitopes on h7 influenza viruses - Google Patents
Monoclonal antibodies targeting neutralizing epitopes on h7 influenza virusesInfo
- Publication number
- SG11201503878XA SG11201503878XA SG11201503878XA SG11201503878XA SG11201503878XA SG 11201503878X A SG11201503878X A SG 11201503878XA SG 11201503878X A SG11201503878X A SG 11201503878XA SG 11201503878X A SG11201503878X A SG 11201503878XA SG 11201503878X A SG11201503878X A SG 11201503878XA
- Authority
- SG
- Singapore
- Prior art keywords
- monoclonal antibodies
- influenza viruses
- antibodies targeting
- neutralizing epitopes
- targeting neutralizing
- Prior art date
Links
- 230000003472 neutralizing effect Effects 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 241000712461 unidentified influenza virus Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261727927P | 2012-11-19 | 2012-11-19 | |
PCT/SG2013/000366 WO2014077777A1 (fr) | 2012-11-19 | 2013-08-23 | Anticorps monoclonaux ciblant des épitopes de neutralisation sur des virus de la grippe h7 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201503878XA true SG11201503878XA (en) | 2015-06-29 |
Family
ID=50731547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201503878XA SG11201503878XA (en) | 2012-11-19 | 2013-08-23 | Monoclonal antibodies targeting neutralizing epitopes on h7 influenza viruses |
Country Status (5)
Country | Link |
---|---|
US (1) | US9637537B2 (fr) |
EP (2) | EP3348568B1 (fr) |
CN (1) | CN105555802B (fr) |
SG (1) | SG11201503878XA (fr) |
WO (1) | WO2014077777A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109988236B (zh) * | 2017-12-30 | 2022-04-01 | 中国科学院天津工业生物技术研究所 | 一种流感病毒抗体的应用 |
CN111154728A (zh) * | 2020-01-13 | 2020-05-15 | 扬州大学 | 用于h7n9亚型禽流感病毒ha多肽竞争抑制elisa抗体检测的单克隆抗体及方法 |
US20240024414A1 (en) * | 2020-09-21 | 2024-01-25 | Icahn School Of Medicine At Mount Sinai | Archaea l30 proteins as universal influenza virus therapeutics |
CN115873104B (zh) * | 2022-08-09 | 2023-07-14 | 华南农业大学 | 针对h7亚型禽流感病毒的纳米抗体m124及其应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
US5843708A (en) | 1988-01-05 | 1998-12-01 | Ciba-Geigy Corporation | Chimeric antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
PL2046833T3 (pl) | 2006-07-14 | 2014-01-31 | Ac Immune Sa | Humanizowane przeciwciało przeciw amyloidowi beta |
AU2008297594B2 (en) * | 2007-09-13 | 2013-06-20 | Temasek Life Sciences Laboratory Limited | Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof |
US8871207B2 (en) * | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
-
2013
- 2013-08-23 WO PCT/SG2013/000366 patent/WO2014077777A1/fr active Application Filing
- 2013-08-23 EP EP18158352.7A patent/EP3348568B1/fr active Active
- 2013-08-23 SG SG11201503878XA patent/SG11201503878XA/en unknown
- 2013-08-23 CN CN201380070832.4A patent/CN105555802B/zh active Active
- 2013-08-23 US US14/442,626 patent/US9637537B2/en active Active
- 2013-08-23 EP EP13855450.6A patent/EP2920207B1/fr active Active
Also Published As
Publication number | Publication date |
---|---|
EP2920207B1 (fr) | 2018-03-21 |
WO2014077777A1 (fr) | 2014-05-22 |
EP2920207A1 (fr) | 2015-09-23 |
CN105555802B (zh) | 2020-08-28 |
EP2920207A4 (fr) | 2016-06-15 |
US20160257731A1 (en) | 2016-09-08 |
CN105555802A (zh) | 2016-05-04 |
EP3348568A1 (fr) | 2018-07-18 |
US9637537B2 (en) | 2017-05-02 |
EP3348568B1 (fr) | 2019-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202109290B (en) | High-concentration monoclonal antibody formulations | |
HK1252895A1 (zh) | 識別α-突觸核蛋白的人源化抗體 | |
BR112015008635A2 (pt) | anticorpos anti-hiv amplamente neutralizantes. | |
EP2857419A4 (fr) | Molécule de liaison d'antigène supprimant un antigène associé | |
ZA201406227B (en) | Humanized antibodies that recognize alpha-synuclein | |
EP2663334A4 (fr) | Anticorps dirigés contre le virus de la grippe | |
EP2768858A4 (fr) | Anticorps antigrippaux | |
EP2828292A4 (fr) | Anticorps de neutralisation dirigés contre le jvc | |
DK2828284T3 (da) | Jcv-neutraliserende antistoffer | |
ZA201507251B (en) | Antibodies targeting m-csf | |
SG11201503878XA (en) | Monoclonal antibodies targeting neutralizing epitopes on h7 influenza viruses | |
HUE049860T2 (hu) | IL-ß-t neutralizáló, humán monoklonális antitestek | |
SG11201400100SA (en) | Dengue-virus serotype neutralizing antibodies | |
SG11201403773WA (en) | Monoclonal antibodies targeting neutralizing epitopes on h5 influenza virus of clade 2.3 | |
SG11201503432SA (en) | Monoclonal antibody against muramyl peptides |